206 related articles for article (PubMed ID: 36039062)
1. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
[TBL] [Abstract][Full Text] [Related]
2. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
Qu F; Liu Q; Lu R; Li W
Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
Li C; Sun L; Liu Z; Sun H; Wang X; Yu Q; Yu Z
Am J Cancer Res; 2024; 14(2):869-879. PubMed ID: 38455400
[TBL] [Abstract][Full Text] [Related]
4. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
[TBL] [Abstract][Full Text] [Related]
5. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.
Fan S; He L; Sang D
Oncol Lett; 2023 Aug; 26(2):359. PubMed ID: 37545624
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
[TBL] [Abstract][Full Text] [Related]
8. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
[TBL] [Abstract][Full Text] [Related]
9. Elderly patients with advanced HER2-positive breast cancer with liver metastases benefit from low dose disitamab vedotin (RC48): case series and literature review.
Qu FJ; Kong Y; Yan X; Wang H
Anticancer Drugs; 2024 May; ():. PubMed ID: 38718261
[TBL] [Abstract][Full Text] [Related]
10. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
Wen F; Lin T; Zhang P; Shen Y
Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
[TBL] [Abstract][Full Text] [Related]
11. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
Hu Y; Zhu Y; Wei X; Tang C; Zhang W
Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.
Hu Y; Chen F; Sun S; Xv L; Wang X; Wang M; Zhao S; Zhao Z; Li M
Front Oncol; 2024; 14():1312634. PubMed ID: 38344201
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
[TBL] [Abstract][Full Text] [Related]
14. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
[TBL] [Abstract][Full Text] [Related]
15. A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
Hong X; Chen X; Wang H; Xu Q; Xiao K; Zhang Y; Chi Z; Liu Y; Liu G; Li H; Fang J; Lin T; Zhang Y
Adv Sci (Weinh); 2023 Nov; 10(32):e2302377. PubMed ID: 37824205
[TBL] [Abstract][Full Text] [Related]
16. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
Wang P; Xia L
BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
[TBL] [Abstract][Full Text] [Related]
17. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
Huang L; Wang R; Xie K; Zhang J; Tao F; Pi C; Feng Y; Gu H; Fang J
Breast Cancer Res Treat; 2022 Jan; 191(1):51-61. PubMed ID: 34657203
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
Xu Y; Wang Y; Gong J; Zhang X; Peng Z; Sheng X; Mao C; Fan Q; Bai Y; Ba Y; Jiang D; Yang F; Qi C; Li J; Wang X; Zhou J; Lu M; Cao Y; Yuan J; Liu D; Wang Z; Fang J; Shen L
Gastric Cancer; 2021 Jul; 24(4):913-925. PubMed ID: 33945049
[TBL] [Abstract][Full Text] [Related]
19. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
[No Abstract] [Full Text] [Related]
20. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
